TXMD - TherapeuticsMD ends agreement with interim CFO but will stay on in consulting role
- An agreement between TherapeuticsMD ( NASDAQ: TXMD ) and its interim CFO Michael Donegan has been terminated.
- Donegan was also serving as chief accounting officer and VP, finance.
- He is also entitled to separation benefits, including his salary for a year and COBRA benefits for two years.
- In a consulting role, Donegan will stay on as principal financial officer and principal accounting officer .
- Seeking Alpha's Quant Rating views TherapeuticsMD ( TXMD ) as a sell.
For further details see:
TherapeuticsMD ends agreement with interim CFO, but will stay on in consulting role